Combining Ipilimumab and Bevacizumab in Glioblastoma: Is it Really Safe and Effective? Author Response

Carter, T.; Shaw, Heather; Mulholland, Paul J.

doi:10.1016/j.clon.2016.07.009

Cited by 5 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This improves efficacy and reduces the usage of steroids to treat CNS inflammation in patients. Bevacizumab and granulocyte colony-stimulating factors (G-CSF) are two medicines used in combination therapy [ 19 ]. The use of temozolomide with ipilimumab to treat newly diagnosed GBM is being investigated in a phase I randomized controlled study.…”

Section: Reviewmentioning

confidence: 99%

Current Advances in Immunotherapy for Glioblastoma Multiforme and Future Prospects

Chowdhury¹,

Bappy²,

Clocchiatti-Tuozzo³

et al. 2021

Cureus

View full text Add to dashboard Cite

Glioblastoma is the most frequent and malignant type of brain tumor. It has a reputation for being resistant to current treatments, and the prognosis is still bleak. Immunotherapies have transformed the treatment of a variety of cancers, and they provide great hope for glioblastoma, although they have yet to be successful. The justification for immune targeting of glioblastoma and the obstacles that come with treating these immunosuppressive tumors are reviewed in this paper. Cancer vaccines, oncolytic viruses (OVs), checkpoint blockade medications, adoptive cell transfer (ACT), chimeric antigen receptor (CAR) T-cells, and nanomedicine-based immunotherapies are among the novel immune-targeting therapies researched in glioblastoma. Key clinical trial outcomes and current trials for each method are presented from a clinical standpoint. Finally, constraints, whether biological or due to trial design, are discussed, along with solutions for overcoming them. In glioblastoma, proof of efficacy for immunotherapy approaches has yet to be demonstrated, but our rapidly growing understanding of the disease's biology and immune microenvironment, as well as the emergence of novel promising combinatorial approaches, may allow researchers to finally meet the medical need for patients with glioblastoma multiforme (GBM).

show abstract

Section: Reviewmentioning

confidence: 99%